- Home
- TRU vs KYMR Comparison
TRU vs KYMR Comparison
Compare TRU & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRU | KYMR |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 10.6B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRU | KYMR |
|---|---|---|
| Price | $65.43 | $111.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 24 |
| Target Price | $92.24 | ★ $139.32 |
| AVG Volume (30 Days) | ★ 2.2M | 716.5K |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ 60.00 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $4,576,300,000.00 | $39,211,000.00 |
| Revenue This Year | $12.88 | $167.23 |
| Revenue Next Year | $7.72 | N/A |
| P/E Ratio | $31.66 | ★ N/A |
| Revenue Growth | ★ 9.38 | N/A |
| 52 Week Low | $60.96 | $55.26 |
| 52 Week High | $89.12 | $130.05 |
Technical Indicators
Market Signals| Indicator | TRU | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 37.37 | 49.77 |
| Support Level | $63.90 | $110.64 |
| Resistance Level | $74.19 | $121.24 |
| Average True Range (ATR) | 2.43 | 5.74 |
| MACD | 0.08 | -0.31 |
| Stochastic Oscillator | 36.81 | 51.63 |
Price Performance
Historical ComparisonAbout TRU TransUnion
TransUnion, along with Equifax and Experian, is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.